Albor A, Kulesz-Martin M. p53 and the development of genomic instability: possible role for topoisomerase interaction. In "DNA alterations in cancer: genetic and epigenetic changes", Section: The contribution of karyotypic instability to cancer formation and tumor progression, Melanie Ehrlich, Ed., BioTechniques Books, Eaton Publishing, 2000

Alm K, Berntsson PSH, Kramer DL, Porter CW, Oredsson SM. Treatment of cells with the polyamine analog N1, N11-diethylnorspermine retards S phase progression within one cell cycle. Eur. J. Biochem. 267(13):4157-4164, 2000

Avantaggiati ML. Meeting Report: Molecular horizons in cancer therapeutics - Eleventh Annual Pezcoller Symposium. Biochem. Biophys. Acta 1470:R49-R59, 2000

Berleth ES, Henn AD, Gurtoo HL, Wollman R, Alderfer JL, Mihich E, Ehrke MJ. A novel tumor necrosis factor-a inhibitory protein, TIP-B1. Intl. J. Immunopharmacology 22(12):1137-1142, 2000

Bernacki RJ, Pera P, Gambacorta P, Brun Y, Greco W. In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. In "The Camptothecins: Unfolding their Anticancer Potential" Ed.: Liehr, Giovanella, and Verschraegen, Annals NY Acad, Sci. 922, 293-297, 2000

Black JD. Protein kinase C-mediated regulation of the cell cycle (Invited Review). Frontiers in Bioscience 5:406-423, 2000

Bucki C, Khinkis L, Malmberg A, Parsons J, Greco WR. Monte Carlo investigation of rival experimental designs for the Hill model. In Monte Carlo Simulation: Proceedings of the International Conference on Monte Carlo Simulation, Monte Carlo, Principality of Monaco, 18-21, June, 2000. (G.I. Schueller & P.D. Panos, eds), A.A. Balkema Publishers, Lisse, The Netherlands 2001, pp. 247 - 253

Cao S, Baccanari DP, Rustum YM, Davis ST, Tansik RL, Porter DJT, Spector T. *-Fluoro-b-Alanine: Effects on the antitumor activity and toxicity of 5-Fluorouracil. Biochem. Pharmacol. 59(8):953-960, 2000

Cao SS, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose. Cancer Res. 60:3717-3721, 2000

Chiang SY, Burli R, Scott G, Gawron L, Benz C, Dervan P, Beerman T. Targeting the ESX Binding Site of the HER2/neu Promoter with Pyrrole-Imidazole Polyamides. J. Biol. Chem. 275:24246-24254, 2000

Darcy KM, Zangani D, Lee PPH, Ip MM. Isolation and culture of normal rat mammary epithelial cells. In: Methods in Mammary Gland Biology and Breast Cancer Research. Editors: Margot M. Ip and Bonnie A. Asch. Kluwer Academic/Plenum Press, New York, 2000, Chapter 16, pp. 163-175

Darcy KM, Zangani D, Shea-Eaton W, Showmaker SF, Lee PPH, Mead LH, Mudipalli A, Megan R, Ip MM. Mammary fibroblasts stimulate growth, alveolar morphogenesis and functional differentiation of normal rat mammary epithelial cells. In Vitro Cell & Devel. Biol. 36:578-592, 2000

Darcy, KM, Zangani D, Wohlhueter AL, Huang RH, Vaughan MM, Russell JA, Ip MM. Changes in ErbB2 (her2/neu), ErbB3 and ErbB4 during growth, differentiation and apoptosis of normal rat mammary epithelial cells. J. Histochem. Cytochem. 48(1):63-80, 2000

Dolnick BJ. Thymidylate synthase and the cell cycle: What should we believe?" Commentary in The Cancer Journal 6:215-216, 2000

Dolnick BJ, Su J. Homo sapiens rTS gene, complete cds, alternatively spliced. GenBank, AF305057, 2000

Ehrke MJ, Verstovsek S, Maccubbin DL, Ujhazy P, Berleth ES, Zaleskis G, Mihich E. Protective specific immunity induced by doxorubicin plus TNF-a combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Intl. J. Cancer 87:101-109, 2000

Frey MR, Clark JA, Leontieva O, Uronis, JM, Black AR, Black JD. Protein kinase C signaling mediates a program of cell cycle withdrawal in the intestinal epithelium. J. Cell Biol. 151:763-777, 2000

Fu MF, Wang CG, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J.Biol.Chem. 275(27):20853-20860, 2000

Gangjee A, Yu J, McGuire JJ, Cody V, Galitsky N, Kisliuk RL, Queener SF. Design, synthesis and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J. Med. Chem. 43:3837-3851, 2000

Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. J. Med. Chem. 43(16):3125-3133, 2000

Gonzalez B, Pajares MA, Hermoso JA, Alvarez L, Garrido F, Sufrin J, Sanz-Aparicio J. The crystal structure of tetrameric methionine adenosyltransferase from rat liver reveals the methionine binding site. J. Mol. Biol. 300(2):363-375, 2000

Guo B, Cao S, Toth K, Azark RA, Rustum YM. Overexpression of Bax Enhances Antitumor Activity of Chemotherapeutic Agents in Human Head and Neck Squamous Cell Carcinoma, Clinical Cancer Research 6:718-724, 2000

Howell PL, Blessing RH, Smith GD, Weeks CM. Optimizing DREAR and SnB parameters for determining selenium atom substructures. Acta Cryst. D56: 604-617, 2000

Ip C, Ip MM, Loftus T, Shoemaker S, Shea-Eaton W. Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. Cancer Epidemiology, Biomarkers and Prev. 9(7):689-696, 2000

Ip MM, Asch BA. Editors. Atlas of Mammary Histology: A special issue of the Journal of Mammary Gland Biology and Neoplasia, 2000

Ip MM, Asch BA. Editors, Methods in Mammary Gland Biology and Breast Cancer Research, Kluwer Academic/Plenum Press, New York, 2000

Kulesz-Martin M F. Molecular markers for colon cancer: where do we go from here?, Editorial Comment, Cancer Investigation 18(3):287-288, 2000

Kuo SR, Liu JS, McHugh MM, Beerman TA, Melendy T. Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication through RPA Inactiviation. J. Biol. Chem. 275(2):1391-1397, 2000

Lee PPH, Hwang JJ, Murphy G, Ip MM. Functional significance of MMP-9 in TNF-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 141: 3764-3773, 2000

Liu Y, Black JD, Kisiel N, Kulesz-Martin MF. Cloning and characterization of SPAF, a novel spermatogenesis associated factor aberrantly induced at the malignant conversion stage of epidermal carcinogenesis. Oncogene 19:1579-1588, 2000

Liu JS, Kuo SR, McHugh MM, Beerman TA, Melendy TJ. Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication through replication protein A inactivation. Biol.Chem. 275(2):1391-1397, 2000

Masso-Welch PA, Darcy KM, Stangle-Castor NC, Ip MM. A developmental atlas of rat mammary gland histology, (An invited review). J. Mammary Gland Biology and Neoplasia 5: 165-186. 2000

McGuire JJ, Balinska M, Russell CA. Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct: expression in antifolate-sensitive and -resistant human cell lines. J. Biol. Chem. 275: 13012-13016, 2000

McGuire JJ, Rustum YR. Comment on the metabolic pathway presented by Wisotzkey et al. (Invited by the Editor). Molec. Diagnosis 5: 6-6, 2000

Mihich E. Historical overview of biological response modifiers. Cancer Investigation 18(3):456-466, 2000

Mihich E. New Leads in Cancer Therapeutics: A Keynote Address. (Presentation during International Symposium, "New directions in cancer management", 7-8 August 2000, Buenos Aires, Argentina), Medicina 60 Supl. II: 4-8, 2000

Mihich E. On the immunomodulating effects of anticancer drugs and their therapeutic exploitation. Invited Editorial, Japanese J Clin Oncol 30(11):469-471, 2000

Mihich E, Ehrke MJ. Anticancer drugs plus cytokines: Immunomodulation based therapies of mouse tumors. Intl. J. Immunopharmacology 22:1077-1081, 2000

Mihich E, Livingston D. Meeting Report: Eleventh Annual Pezcoller Symposium: Molecular horizons in cancer therapeutics. Cancer Res. 60:768-773, 2000

Mihich E, Tominaga S, Zanker KS, Zhang Y. International symposium on biology of cancer prevention and treatment: Meeting Report. Intl. J. Cancer 87:457-460, 2000

Minderman H, Wrzosek C, Cao SS, Utsugi T, Kobunai T, Yamada Y, Rustum YM. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemotherapy & Pharmacology 45(1):78-84, 2000

Ojima I, Lin S, Slater JC, Wang T, Pera P, Bernacki RJ, Ferlini C, Scambia G. Synthesis and biological activity of C-3'-difluoromethyl-taxoids. Bioorg. Med. Chem. Lett. 8:1619-1628, 2000

Pignatello R, Spampinato G, Sorrenti V, Di Giacomo C, Vicari L, McGuire JJ, Russell CA, Puglisi G, Toth I. Lipophilic methotrexate conjugates with antitumor activity. Eur. J. Pharmaceut. Sci. 10: 237-245, 2000

Slocum HK, Parsos JC, Winslow EO, Brodrick L, Minderman H, Toth K, Greco WR, Rustum YM. Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with Raltitrexed (ZD-1694). Cytometry 41:252-260, 2000

Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, Schneider E. Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 60(13):3514-3521, 2000

Von Dreele RB, Stephens PW, Smith GD, Blessing RH. The first protein crystal structure determined from high-resolution X-ray powder diffraction data: a variant of T3R3 human insulin-zinc complex produced by grinding. Acta Cryst. D. 56:1549-1553, 2000

Vujcic S, Halmekto, Janne J, Porter CW. Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth and sensitivity to polyamine analogs. J. Biol. Chem. 275:38319-38328, 2000

White C, Heidenreich O, Nordheim A, Beerman T A. Use of the c-fos serum response element as a model system to evaluate the effectiveness of DNA binding drugs to inhibit transcription. Biochemistry 39:12262-12273, 2000

Yarlett N, Martinez MP, Goldberg B, Kramer D, Porter CW. Spermidine dependence of Trichomonas vaginalis upon polyamine backconversion. Microbiology 146:2715-2722, 2000

Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol.Pharmacol. 57(3):453-459, 2000